Alumis Inc.
ALMS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$11.10
▼ -2.29%
P/E
-2.92
Mkt Cap
$1.4B
52-Wk Range
$3.76–$31.35
52-Week Range
$3.76 - $31.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 156.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary allosteric TYK2 inhibitor mechanism with potentially improved safety and efficacy profiles
- CNS-penetrant A-005 candidate addressing underserved neuroinflammatory disease markets
- Focused pipeline targeting high-prevalence autoimmune indications with significant unmet medical needs
Bear Case
1 risk
- Low volatility (beta -0.7).
Growth
Mild headwinds expected
Clinical trial progression and regulatory milestones for ESK-001 across multiple indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-41.5% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ALMS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 12, 2026
Most recent quarter reported revenue of $1.7M (-38% YoY). Reported EPS of -$1.11. Gross margin 0.0%.
Reported EPS · last 4Q
Q2 26
-$1.11
Q1 26
-$0.74
Q4 25
-$0.89
Q3 25
-$1.06
Revenue trend · last 8Q
—
—
—
—
—
—
-90%
-38%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$17.4M
$2.7M
$2.1M
$1.9M
$1.7M
$1.7M
Margins · last 8Q
Gross
0.0%
Profit
-8557.2%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Sep 3, 2026
vs Industry
How ALMS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related